AptarGroup : Investor Relations Presentation - Q1 2024

Investor Relations

Q1 2024

Forward Looking Statements & Non-GAAP Financial

Measures

This presentation includes forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management's beliefs and assumptions in light of information currently available to management. Accordingly, the Company's actual results may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in the Company's operations and business environment, including, among other factors, those described in documents filed by the Company with the Securities and Exchange Commission, specifically its Form 10-Ks and

10-Qs. The Company does not assume any obligation to update, amend or clarify such statements to reflect new events, information or circumstances after the date of this presentation.

During the course of this presentation, certain non-GAAP financial information will be presented. Refer to the Appendix at the end of this presentation for additional information and a reconciliation to the most directly comparable GAAP measures. However, we are not able to reconcile forward-looking non- GAAP financial measures because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates and changes in the fair value of equity investments, or reliably predicted without unreasonable effort because they are not part of the company's routine activities, such as restructuring and acquisition costs. The variability of these items could have a significant impact on our future GAAP financial results.

Adjusted EBITDA and EPS exclude the impact of restructuring initiatives, acquisition related costs, certain purchase accounting adjustments related to acquisitions and investments and net unrealized investment gains and losses related to observable market price changes on equity securities. Adjusted EPS also neutralizes the impact of foreign currency translation effects when comparing current results to the prior year, and further adjusts for the net effect of a tax payment related to a legal entity reorganization. Prior year Adjusted EPS includes foreign currency effects that are approximations of the adjustment necessary to state the prior year earnings per share using current period foreign currency exchange rates. Core sales exclude acquisitions and changes in foreign currency sales. Free cash flow is calculated as cash provided by operating activities less capital expenditures plus proceeds from government grants related to capital expenditures. Return on Investment Capital (ROIC) is calculated as Adjusted Earnings before Net Interest and Taxes, less Tax Effect / Average Capital, whereas Average Capital is the average of beginning of year capital and Capital is Equity plus Debt less Cash.

2

Transforming ideas into solutions that

improve everyday life

Aptar is a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care.

3

75+ Years of Innovation

A market leading, proprietary dosing and precision dispensing company

Proprietary Dosing & Dispensing		Precision Consumer Dispensing		Dispensing Closures

4 4

Aptar Snapshot

$3.5B

2023 Annual Revenue

5,000+

Customers

20%

Adjusted EBITDA / Sales %

FY 2023

1-3x

Leverage Corridor

Long-Term Target

30-40%

Dividend Payout Ratio1

31st Year

in 2024 of Paying an Increasing

Total Dividend Annually

2

We are focused on creating long-term value for our stakeholders.

1: Cash dividends paid per share / adjusted earnings per share.	5
2: Logo reprinted with permission of Barron's.

Global Presence and Customer Base

Q1 2024 Net Sales by Ship To Destination

EMEA

52%

North	Asia
10%
America
30%	Latin America

8%

Over 13,500 dedicated employees in

20 countries

• Europe: 8,200
• Asia/Latin America: 2,800
• North America: 2,500

Significant history and global presence enables us to build solid and lasting credibility with regional and global powerhouse customers

• Over 5,000 global customers
• Many of the world's leading brands

6

Technology-based Innovation Leader

We combine product design, engineering and science to create core differentiating technologies which we leverage across a variety of end markets.

Over

7,000

active patents*

Focused on

INNOVATION

3%

of FY 2023 revenue invested in

R&D

Aimed at global megatrends, including:

Sustainability Health + Wellness Digitalization Urbanization Changing Demographics

e-Commerce/Individualization

Improving the daily lives of

MILLIONS OF PATIENTS AND CONSUMERS

ATTRACTIVE GROWING END MARKETS

	Home Care,
Beverage, 4%	3%
Active Material	Proprietary Drug
Science Solutions, 5%
Delivery Devices**,
	31%
Injectables, 8%

Food, 11% $3.5B*

Personal Care,
16%	Beauty, 23%

*2023 Annual Revenue

**Proprietary Drug Delivery Devices includes Prescription, Consumer Health Care, and Digital Health Markets

*Granted and pending as of March 2024 based on company data and publicly available information	7

Q1 2024 Financial Highlights

+6%

Reported Sales Growth

+50%

Reported Earnings Per

Share Growth

+5%

Core Sales Growth*

+31%

Adjusted Earnings Per

Share Growth*

Highlights:

• Off to a great start for the year
• Strong demand for Pharma's proprietary drug delivery systems and improved performance of the injectables unit
• Recovery in certain North American consumer end- markets
• Teams remain focused on cost management and improving operational leverage
• Decreased selling, general and administrative (SG&A) expenses as a percentage of sales over the prior year quarter

* See accompanying slide titled: Forward Looking Statements & Non-GAAP Financial Measures.	8

Sustainability Recognition

Barron's	CDP		Capital	Newsweek	Forbes	EcoVadis	3BL Media	ISS ESG	USA Today	Le Point
In the Top 100	Recognized as a		France	In the Top 100	One of the	Sustainability Rating	One of the	Achieved	One of the Top	One of the Most
Most Sustainable	Supplier		Named a	America's Most	World's Top	Platinum	100 Best	Prime	25 of America's	Responsible
Companies	Engagement		Company	Responsible	Companies For	Top 1%	Corporate	Status	Climate Leaders	Companies
from 2019-2024	Leader	Committed to	Companies	Women	since 2021	Citizens	from 2020-2023	2023	in France
	2020-2023		Diversity	2020-2024	from 2021-2023		from 2021-2023			2020-2023
			In 2023

Logo above reprinted with permission of Barron's

9

Recent Innovations and Solutions on the Market

Aptar Pharma

• Aptar's China Pharma regulation supported Airless+ CS system is the drug delivery solution used to treat rosacea, recently approved by the National Medical Products Administration in China
• Our proprietary ophthalmic squeeze dispenser is used for AbbVie's Refresh® brand of an OTC lubricant eye drop treatment in the US
• Aptar's PureHale® technology is used to dispense Frida Baby's ultra-fine, natural sterile saline mist in children's cough and cold in the
  US
• In Turkey, our nasal spray pump is used to deliver a new allergic rhinitis treatment, Fixriva®

Aptar Beauty

• Coty's new Marc Jacob Daisy Wild fragrance features our fragrance pump, custom overcap and colored dip-tube to match the flower stalks
• Aptar's recyclable airless dispensing system is the solution for Avene's dermo- cosmetic rosacea solution
• Our reloadable airless technology is featured on a skincare launch by Chinese beauty brand, Zhiben
• Our fully recyclable lotion pump is the dispensing solution for the new Papatui men's skincare line in the US

Aptar Closures

• Aptar's sports cap is the dispensing solution for PepsiCo's new Gatorade Water in the

US

• Our mono-material, tamper evident closure is featured on a line of Voss® water in the US
• Aptar's fully recyclable tube top is used for Unilever's St. Ive's® brand skin scrub in the
  US
• Our tamper-evident,snap-top closure that features a customizable in-molded scoop is featured on Nutrapharm's protein supplement in Latin America

10